Stocks News

LAST PRICE
0.3570
TODAY'S CHANGE (%)
Trending Down-0.0130 (-3.5203%)

Bid / Lots
0.3200/ 47
Ask / Lots
0.3693/ 25
Open / Previous Close
0.3693 / 0.3700
Day Range
Low 0.3200
High 0.3693
52 Week Range
Low 0.3000
High 38.0000
Volume
777
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 31, 2024
- Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: PBLA
  
  Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
  
  MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024.

Today
- ZyVersa Says Data Show Inflammasome Inhibition May Slow Obesity-Linked Diabetes; Shares Jump, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: ZVSA
- Top Premarket Gainers, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: QNST, ZVSA, ALAB, ALBT
- ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: ZVSA
Oct 29, 2024
- ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs, from 7:57AM ET on Tuesday Oct 29, 2024 by Dow Jones
  7:57AM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: ZVSA
Oct 22, 2024
- ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases, from 7:57AM ET on Tuesday Oct 22, 2024 by Dow Jones
  7:57AM ET on Tuesday Oct 22, 2024 by Dow Jones
  Companies Mentioned: ZVSA
Oct 17, 2024
- ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months, from 7:50AM ET on Thursday Oct 17, 2024 by Dow Jones
  7:50AM ET on Thursday Oct 17, 2024 by Dow Jones
  Companies Mentioned: ZVSA
Oct 15, 2024
- ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors, from 7:50AM ET on Tuesday Oct 15, 2024 by Dow Jones
  7:50AM ET on Tuesday Oct 15, 2024 by Dow Jones
  Companies Mentioned: ZVSA
Oct 10, 2024
- Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project, from 9:15AM ET on Thursday Oct 10, 2024 by Dow Jones
  9:15AM ET on Thursday Oct 10, 2024 by Dow Jones
  Companies Mentioned: PHBI
Oct 8, 2024
- Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, from 4:16PM ET on Tuesday Oct 08, 2024 by Accesswire
  4:16PM ET on Tuesday Oct 08, 2024 by Accesswire
  Companies Mentioned: DRMA
- Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, from 4:16PM ET on Tuesday Oct 08, 2024 by Dow Jones
  4:16PM ET on Tuesday Oct 08, 2024 by Dow Jones
  Companies Mentioned: DRMA

Panbela Therapeutics Inc
OTCQB:PBLAUnited States

Search Criteria

Oct 31, 2024

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Peers Headlines

Today

ZyVersa Says Data Show Inflammasome Inhibition May Slow Obesity-Linked Diabetes; Shares Jump, from 6 hours ago by MT Newswires

Top Premarket Gainers, from 8 hours ago by MT Newswires

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes, from 9 hours ago by Dow Jones

Oct 29, 2024

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs, from 7:57AM ET on Tuesday Oct 29, 2024 by Dow Jones

Oct 22, 2024

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases, from 7:57AM ET on Tuesday Oct 22, 2024 by Dow Jones

Oct 17, 2024

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months, from 7:50AM ET on Thursday Oct 17, 2024 by Dow Jones

Oct 15, 2024

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors, from 7:50AM ET on Tuesday Oct 15, 2024 by Dow Jones

Oct 10, 2024

Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project, from 9:15AM ET on Thursday Oct 10, 2024 by Dow Jones

Oct 8, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, from 4:16PM ET on Tuesday Oct 08, 2024 by Accesswire

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, from 4:16PM ET on Tuesday Oct 08, 2024 by Dow Jones